Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2001

View Archived Issues

Delta Pharmaceuticals reports name change

Pharmacological profile of Ono-6818, an orally active HNE inhibitor, discussed at ATS meeting

Tripep provides update on lead drug candidate GPG

Viozan produces rapid and sustained activation of D2 receptors and beta2-adrenoceptors

Prostanoid receptor agonist protects against warm ischemia-reperfusion injury in rat kidneys

Company Profile: Apovia

Bimosiamose blocks kidney allograft rejection and is synergistic with other agents

Sepracor seeks FDA approval to evaluate new anxiolytic in humans

Ergo Science looking to sell or license Ergoset property rights

Posttranscriptional TNF inhibitor advances towards clinical trials for IBD

Femara approved in Canada as first-line treatment for advanced breast cancer

ID Biomedical begins clinical evaluation of intranasal influenza vaccine

Curcumin may have additional potential in acute pancreatitis

Hybridon completes sale of remaining shares in MethylGene

Development and commercialization rights to ISIS-113715 licensed by Merck

Dual antiinflammatory and antiproliferative effects reported for sPLA2 inhibitor

Dynavax initiates two new phase II/III trials for ragweed allergy treatment

Company Profile: EluSys Therapeutics

First patent for oral gene delivery owned by Genteric

Atherosclerosis inhibited by anti-MCP-1 gene therapy

Peptides based on Mcep sequence and use in tuberculosis vaccines

Ergoline derivatives synthesized at Novartis useful in depression, anxiety, etc.

Orally active, nontoxic antimicrobial agents in the Aventis pipeline

Merck describes new integrin receptor antagonists and therapeutic use thereof

Kissei researchers identify potential new treatments for diabetes and related disorders

Erythromycin derivatives with potent activity against staphylococci and streptococci

New serotonergic agents from BASF covered by U.S. patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...